NeoGenomics, Inc. (NEO) Stake Lessened by Artisan Partners Limited Partnership
Artisan Partners Limited Partnership lowered its position in NeoGenomics, Inc. (NASDAQ:NEO) by 3.7% during the second quarter, according to its most recent filing with the SEC. The firm owned 2,363,238 shares of the medical research company’s stock after selling 89,602 shares during the period. Artisan Partners Limited Partnership owned 2.98% of NeoGenomics worth $21,175,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also recently modified their holdings of NEO. Teachers Advisors LLC lifted its position in shares of NeoGenomics by 0.4% in the 4th quarter. Teachers Advisors LLC now owns 93,314 shares of the medical research company’s stock worth $800,000 after purchasing an additional 396 shares during the period. Suntrust Banks Inc. lifted its position in shares of NeoGenomics by 0.6% in the 1st quarter. Suntrust Banks Inc. now owns 31,617 shares of the medical research company’s stock worth $249,000 after purchasing an additional 184 shares during the period. Gamco Investors INC. ET AL lifted its position in shares of NeoGenomics by 14.9% in the 1st quarter. Gamco Investors INC. ET AL now owns 77,000 shares of the medical research company’s stock worth $608,000 after purchasing an additional 10,000 shares during the period. Trexquant Investment LP acquired a new position in shares of NeoGenomics in the 1st quarter worth approximately $178,000. Finally, Nordea Investment Management AB lifted its position in shares of NeoGenomics by 30.9% in the 1st quarter. Nordea Investment Management AB now owns 184,271 shares of the medical research company’s stock worth $1,454,000 after purchasing an additional 43,468 shares during the period. Hedge funds and other institutional investors own 80.41% of the company’s stock.
In other NeoGenomics news, Director Alison L. Hannah purchased 20,000 shares of the company’s stock in a transaction that occurred on Thursday, July 27th. The stock was bought at an average price of $9.19 per share, with a total value of $183,800.00. Following the completion of the purchase, the director now directly owns 38,782 shares of the company’s stock, valued at approximately $356,406.58. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 12.20% of the company’s stock.
Shares of NeoGenomics, Inc. (NASDAQ NEO) opened at 10.84 on Thursday. NeoGenomics, Inc. has a 1-year low of $6.90 and a 1-year high of $11.63. The stock has a 50 day moving average of $9.78 and a 200 day moving average of $8.56. The company’s market cap is $860.57 million.
NeoGenomics (NASDAQ:NEO) last announced its quarterly earnings results on Tuesday, July 25th. The medical research company reported $0.04 EPS for the quarter, topping analysts’ consensus estimates of $0.01 by $0.03. NeoGenomics had a positive return on equity of 6.09% and a negative net margin of 2.81%. The company had revenue of $66.09 million during the quarter, compared to analyst estimates of $62.95 million. During the same quarter last year, the firm posted $0.04 earnings per share. The firm’s revenue was up 4.7% on a year-over-year basis. Analysts predict that NeoGenomics, Inc. will post $0.18 EPS for the current year.
NEO has been the subject of several research analyst reports. Zacks Investment Research upgraded shares of NeoGenomics from a “sell” rating to a “hold” rating in a research note on Saturday, July 29th. BidaskClub lowered shares of NeoGenomics from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, September 13th. Gabelli initiated coverage on shares of NeoGenomics in a research note on Thursday, August 24th. They issued a “buy” rating and a $9.00 price objective for the company. ValuEngine upgraded shares of NeoGenomics from a “sell” rating to a “hold” rating in a research note on Friday, June 23rd. Finally, Cantor Fitzgerald set a $11.00 price objective on shares of NeoGenomics and gave the company a “buy” rating in a research note on Saturday, May 27th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $10.20.
NeoGenomics Company Profile
NeoGenomics, Inc is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee.
Receive News & Ratings for NeoGenomics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.